2 Immunotherapies Show Comparable Benefits in Extensive-Stage Small Cell Lung Cancer“Key Takeaways: PD-1 and PD-L1 inhibitors combined with chemotherapy significantly improve survival in ES-SCLC compared with chemotherapy alone. No significant difference in overall...
Lung Cancer Among Non-Smokers Increasing“Rates of lung cancer diagnoses among people who have never smoked are rising, according to the World Health Organization’s cancer agency. The International Agency for Research on Cancer (IARC) estimates that lung cancer is now...
Does Your Home Harbor a Killer?“HIGH POINT, N.C., Jan. 28, 2025 /PRNewswire/ — January is Radon Action Month, a vital time for individuals and communities to learn about radon risks and take action. This week, designated as National Radon Awareness Week by the...
Protecting Medicaid for People with Lung Cancer“When Wynn first went to the hospital for a collapsed lung, she didn’t have health insurance and believed that she did not get the care she needed. Doctors did an x-ray and dealt with the immediate problem, but did not...
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer “TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq:...
J&J says its lung cancer drug combination keeps people alive longer“Key Points: Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca’s Tagrisso in a clinical trial....
More News and Updates